Using an antiparasitic drug to enhance Hepatitis vaccination

Effect of levamisole supplementation on hepatitis B virus vaccination response in chronic renal failure patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306296388N5

Enrollment

Registered

2013-07-09

Start date

2013-05-29

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure. Chronic kidney disease

Interventions

Intervention 1: For control group: 3-episode vaccination with 40 micrograms of recombinant subcutaneous vaccine in months 0, 1 and 6 after the initiation of the study will be administered. Interventi

Prevention

Treatment - Drugs

For control group: 3-episode vaccination with 40 micrograms of recombinant subcutaneous vaccine in months 0, 1 and 6 after the initiation of the study will be administered.

For intervention group: In addition to 3-episode hepatitis B vaccination with 40 micrograms of recombinant subcutaneous vaccine in months 0, 1 and 6 after the initiation of the study, oral levamisole

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (being negative for hepatitis B antibody; to suffer from chronic renal failure without any prior history for hepatitis B vaccination) Exclusion criteria: (to have antibody titer more than 10 international units or having a history of hepatitis B vaccination; having clues for any autoimmune or other systemic disease; having a positive history for immunosuppressive drugs consumption in the last 6 months)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HBs antigen titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HBs antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HBc antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HCV antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HIV antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.	—

Measure

Time frame

HBs antigen titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HBs antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HBc antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HCV antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.;HIV antibody titer. Timepoint: at the start of the study and one month after each vaccination episode. Method of measurement: Laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Moghaddaszadeh

Tabriz University of Medical Sciences

m_moghadaszadeh@hotmail.com+98 41 1335 7310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026